In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-04-19 , DOI: 10.1093/jac/dkaa119
Qiwen Yang ₁ , Yingchun Xu ₁ , Peiyao Jia _{1,

2} , Ying Zhu ₁ , Jingjia Zhang ₁ , Ge Zhang ₁ , Jun Deng ₃ , Meredith Hackel ₄ , Patricia A Bradford ₅ , Harald Reinhart ₃

Affiliation

Durlobactam is a broad-spectrum inhibitor of class A, C and D β-lactamases. Sulbactam is a generic β-lactam most commonly used as a β-lactamase inhibitor in combination with ampicillin; however, it has a unique property in that it has selective intrinsic activity against Acinetobacter baumannii. Currently, there is widespread resistance caused by multiple β-lactamases including class A carbapenemases and class C and class D enzymes. The addition of durlobactam to sulbactam restores in vitro activity against MDR A. baumannii that possess multiple β-lactamases.

更新日期：2020-06-19

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11